These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 16170195)

  • 81. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
    J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer.
    Montemurro F; Aglietta M
    Clin Breast Cancer; 2005 Apr; 6(1):77-80. PubMed ID: 15899075
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
    Yaal-Hahoshen N; Safra T
    Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
    [No Abstract]   [Full Text] [Related]  

  • 84. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
    Tamura K
    Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
    [No Abstract]   [Full Text] [Related]  

  • 85. [Advances in herceptin neoadjuvant therapy and adjuvant therapy of breast cancer].
    Wang LP; Shen KW; Shen ZZ
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):241-3. PubMed ID: 16875618
    [No Abstract]   [Full Text] [Related]  

  • 86. [Significance of cytostatic drug dose in adjuvant chemotherapy of breast carcinoma].
    Thomssen C
    Geburtshilfe Frauenheilkd; 1996 Jul; 56(7):M102-5. PubMed ID: 8964443
    [No Abstract]   [Full Text] [Related]  

  • 87. [Future direction of adjuvant chemotherapy for breast cancer following new risk categories of St. Gallen Consensus].
    Osaki A; Saeki T
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():407-13. PubMed ID: 17682185
    [No Abstract]   [Full Text] [Related]  

  • 88. Shrinking the tumor, shrinking the patient sample size: the early disclosure dilemma.
    Puglisi F; de Azambuja E; de Castro G; Demonty G
    J Clin Oncol; 2005 Sep; 23(27):6803-4; author reply 6804-5. PubMed ID: 16170195
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 5.